What we do Trident Lifeline Ltd markets and distributes ethical pharmaceutical products domestically and internationally, focusing on formulations via contract manufacturing and a robust export presence. |
Founded in 2,014 |
Market share Strong emerging pharmaceutical exporter with growing product registrations across 44 countries in Africa, Latin America, Asia, and other regions. |
Problem solved Provides high-quality, affordable pharmaceutical products globally, addressing healthcare needs through diversified formulations and accessible medicines. |
Top clients or who we serve B2B and B2C channels including exporters, distributors, and healthcare providers primarily in India, Africa, Latin America, and East Asia. |
Key management Mr. Hardik Jigishkumar Desai (Chairman & Executive Director), Mr. Shravan H Patel (Managing Director), Mrs. Rupaben Chetan Jariwala (Whole Time Director). |
Our journey and innovations Started as Private Limited in 2014, became Public Limited in 2022, expanded via strategic acquisitions and subsidiaries enhancing manufacturing and product portfolio. |
Where we operate India, Africa (Ghana, Kenya, Cameroon), Latin America (Venezuela, Peru, Bolivia, Chile), Asia (Cambodia, Myanmar), and others totaling 44 countries. |
Top products or what we offer Capsules, tablets, syrups, ointments, gels, mouthwash across therapeutic areas like anti-bacterial, anti-malarial, anti-diabetic, multivitamins, and NSAIDs. |
Top brands Own pharmaceutical brands marketed globally with over 1000 registered products; consistent focus on tablets and capsules as main revenue drivers. |
Raw materials needed Pharmaceutical ingredients, excipients, packaging materials for capsules, tablets, syrups, ointments, and injectables. |
Raw materials supplier Contract manufacturers approved by FDA/WHO and suppliers adhering to quality standards. |
Recurring vs cyclical contribution Revenue predominantly recurring through long-term contracts and continuous product registrations with varied lifecycle stages. |
Our industry position Niche player expanding rapidly in pharmaceutical exports, leveraging contract manufacturing and product registration foothold. |
Financial highlights FY25 revenue ₹70.94 Cr with net profit ₹13.05 Cr; Q3FY26 revenue ₹24.56 Cr, 44% YoY growth; strong EBITDA margins around 29%. |
Geographical revenue split Revenue mainly from India (25%), Venezuela (25%), Ghana (12%), Kenya (10%), Peru (9%) and other markets. |
Order book - |
Whats driving growth Increasing product registrations globally, strategic acquisitions, expanding manufacturing capacity, and growing export markets. |
Our future plans Capex in own and third-party manufacturing, expanding product portfolio, strengthening sales and distribution infrastructure, boosting international registrations. |
Our green promise Committed to regulatory compliances and sustainable practices; specific ESG initiatives not detailed. |
Our people and values Diverse and experienced leadership with focus on ethical practices and workplace safety; commitment to inclusion and employee welfare. |
Key challenges ahead Regulatory approvals timelines, competition in pharma exports, supply chain dependencies on contract manufacturers, managing working capital. |
Interesting facts Has over 2500 products under registration in 44 countries and completed five strategic acquisitions since 2022. |
Risks and strategy Mitigates regulatory and operational risks via diversified markets, certified contract manufacturing, and robust compliance frameworks. |
